Abstract View

Author(s): Abishek S1*1, S.Lavanya22, Balakrishnan R33

Email(s): 1abisheksaravanan3@gmail.com

Address:

    1. M.Pharm, Department of Pharmacy Practice, PSG College of Pharmacy,Coimbatore 2. Professor, Department of Pharmacy Practice, PSG College of Pharmacy, Coimbatore 3. Head and Department of Neurology, PSG Hospital, Coimbatore

Published In:   Volume - 4,      Issue - 6,     Year - 2025

DOI: https://doi.org/10.71431/IJRPAS.2025.4608  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
There are few treatment options for ischemic stroke, which mostly focuses on reperfusion, and it continues to be a leading cause of mortality and permanent disability globally. Neuroprotective medicines are desperately needed in order to improve functional recovery and encourage brain restoration. The capacity of sovateltide, a novel selective endothelin B (ETB) receptor agonist, to promote neurogenesis, angiogenesis, and decrease neuronal death has made it a viable candidate. This review synthesizes current preclinical and clinical evidence regarding the efficacy and safety of sovateltide in ischemic stroke management. Preclinical studies in rodent models demonstrated significant reductions in infarct size, improved motor function, increased expression of neurotrophic factors, and enhanced neural stem cell proliferation. According to clinical data from Phase II and III randomized controlled trials, patients receiving sovateltide had noticeably better functional outcomes than those receiving standard care alone, as indicated by the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel Index. Importantly, no major adverse effects were reported, supporting its favorable safety profile. These findings indicate that sovateltide offers neuroprotective benefits beyond current reperfusion therapies. Future large-scale trials and long-term follow-up studies are warranted to confirm its therapeutic potential and optimize its clinical use in ischemic stroke treatment.

Cite this article:
Abishek S, S.Lavanya, Balakrishnan R. Neuroprotective Role of Sovateltide in Ischemic Stroke: A Review of Preclinical and Clinical Evidence. IJRPAS, June 2025; 4 (6): 80-85.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4608


1.      Mergenthaler P, Dirnagl U, Kunz A. Ischemic stroke: basic pathophysiology and clinical implication. InNeuroscience in the 21st century: From basic to clinical 2022 Oct 18 (pp. 3807-3827). Cham: Springer International Publishing.

2.      Tsivgoulis G, Katsanos AH, Sandset EC, Turc G, Nguyen TN, Bivard A, Fischer U, Khatri P. Thrombolysis for acute ischaemic stroke: current status and future perspectives. The Lancet Neurology. 2023 May 1;22(5):418-29.

3.      Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke—renewed hope in the reperfusion era. Nature Reviews Neurology. 2022 Apr;18(4):193-202.

4.      Ranjan AK, Briyal S, Khandekar D, Gulati A. Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke. Canadian Journal of Physiology and Pharmacology. 2020;98(9):659-66.

5.      Ranjan AK, Briyal S, Gulati A. Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke. Scientific reports. 2020 Jul 29;10(1):12737.

6.      Mavridis T, Mavridi A, Karampela E, Galanos A, Gkiokas G, Iacovidou N, Xanthos T. Sovateltide (ILR-1620) Improves Motor Function and Reduces Hyperalgesia in a Rat Model of Spinal Cord Injury. Neurocritical Care. 2024 Oct;41(2):455-68.

7.      Ramos MD, Briyal S, Prazad P, Gulati A. Neuroprotective effect of sovateltide (IRL 1620, PMZ 1620) in a neonatal rat model of hypoxic-ischemic encephalopathy. Neuroscience. 2022 Jan 1;480:194-202.

8.      Gulati A, Agrawal N, Vibha D, Misra UK, Paul B, Jain D, Pandian J, Borgohain R. Safety and efficacy of sovateltide (IRL-1620) in a multicenter randomized controlled clinical trial in patients with acute cerebral ischemic stroke. CNS drugs. 2021 Jan;35:85-104

9.      Gulati A, Adwani SG, Vijaya P, Agrawal NR, Ramakrishnan TC, Rai HP, Jain D, Sundarachary NV, Pandian JD, Sardana V, Sharma M. Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial. Drugs. 2024 Dec;84(12):1637-50.

10.  Haupt M, Gerner ST, Bähr M, Doeppner TR. Neuroprotective strategies for ischemic stroke—future perspectives. International journal of molecular sciences. 2023 Feb 22;24(5):4334.

11.  Ranjan AK, Gulati A. Sovateltide mediated endothelin B receptors agonism and curbing neurological disorders. International Journal of Molecular Sciences. 2022 Mar 15;23(6):3146.

12.  Berlet R, Anthony S, Brooks B, Wang ZJ, Sadanandan N, Shear A, Cozene B, Gonzales-Portillo B, Parsons B, Salazar FE, Lezama Toledo AR. Combination of stem cells and rehabilitation therapies for ischemic stroke. Biomolecules. 2021 Sep 6;11(9):1316.

Related Images:



Recent Images



RPHPLC Method for Concurrent Determination of Haloperidol and Trihexyphenidyl in API and Combined Tablet Formulations
A review on HPLC Methods for Estimation of Travoprost  in Combined and Single Pharmaceutical formulation and Bulk
To Study number and types of refund Medicines from different Wards of Hospital to the In-Patient Pharmacies
A Novel RP-HPLC Analytical Method Development and Validation of Berberine In Bulk and Polyherbal Formulation
Formulation and Evaluation of A Polyherbal Cough Syrup with Potential Anti-Obesity Effects
Formulation and evaluation of Herbal Face Cream
Formulation and In-vitro Evaluation of Cold Cream
Prevalence study of Diabetes Mellitus
Design and Optimization of Extended-Release Mini-Tablets of Metoprolol Succinate Using Okra Stalk Powder and HPMC K100 M as Release Modifiers
Comprehensive review on Alfuzosin quantification: Analytical techniques and the evolution of AQbD in method development

Tags


Recomonded Articles:

Author(s): Shruti Khot; Rutuja Sawant; Prerana Pawar; Rutuja Pandhare; Swati Vajarde

DOI:         Access: Open Access Read More

Author(s): Ankitha .V1;Narendra Reddy. A1; Yalmaji .21Madhu Harika. B1*

DOI: https://doi.org/10.71431/IJRPAS.2025.4206         Access: Open Access Read More

Author(s): Noor Mohammad Shaikh*; Shaikh Muzammil; Shaikh Mohammad Sofi Ali

DOI: https://doi.org/10.71431/IJRPAS.2025.4405         Access: Open Access Read More

Author(s): Dr. Sundhararajan; Seraphine Joyce J*; Gopinath C; Gowtham B; Guruprasath. R

DOI: https://doi.org/10.71431/IJRPAS.2025.4306         Access: Open Access Read More

Author(s): Vishakha Tyagi1, Yashvardhan Vats1, Qurratul Ain1, Vipin Kumar1, Shabnam Ain1* Raj Kumar Garg2 and Sneha Pandey1

DOI: https://doi.org/10.71431/IJRPAS.2025.4504         Access: Open Access Read More

Author(s): Praful Nilkanth Giradkar

DOI:         Access: Open Access Read More

Author(s): Nidhi Ruhela, Vipin Kumar, Shabnam Ain*, Qurratul Ain, Sneha Pandey, Bhuvnesh, Vishakha Tyagi, Ajeet, Babita Kumar

DOI: https://doi.org/10.71431/IJRPAS.2025.4502         Access: Open Access Read More

Author(s): Praful Nilkanth Giradkar

DOI:         Access: Open Access Read More